JP2018512168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512168A5 JP2018512168A5 JP2017564951A JP2017564951A JP2018512168A5 JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5 JP 2017564951 A JP2017564951 A JP 2017564951A JP 2017564951 A JP2017564951 A JP 2017564951A JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- claudin
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157911.7A EP3064507A1 (en) | 2015-03-06 | 2015-03-06 | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| EP15157911.7 | 2015-03-06 | ||
| PCT/EP2016/054729 WO2016142314A1 (en) | 2015-03-06 | 2016-03-07 | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512168A JP2018512168A (ja) | 2018-05-17 |
| JP2018512168A5 true JP2018512168A5 (https=) | 2019-04-11 |
| JP6757338B2 JP6757338B2 (ja) | 2020-09-16 |
Family
ID=52629425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564951A Expired - Fee Related JP6757338B2 (ja) | 2015-03-06 | 2016-03-07 | 結合タンパク質と、ＩＬ１５Ｒαに対する低下した親和性を有するインターロイキン１５ポリペプチドとを含む融合タンパク質、及び、その治療的使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10906952B2 (https=) |
| EP (2) | EP3064507A1 (https=) |
| JP (1) | JP6757338B2 (https=) |
| CN (1) | CN107636015A (https=) |
| BR (1) | BR112017018975A2 (https=) |
| CA (1) | CA2978808A1 (https=) |
| CY (1) | CY1122494T1 (https=) |
| DK (1) | DK3265478T3 (https=) |
| ES (1) | ES2763598T3 (https=) |
| HR (1) | HRP20192190T1 (https=) |
| HU (1) | HUE047818T2 (https=) |
| PL (1) | PL3265478T3 (https=) |
| PT (1) | PT3265478T (https=) |
| RS (1) | RS59658B1 (https=) |
| SI (1) | SI3265478T1 (https=) |
| WO (1) | WO2016142314A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| AU2018338786A1 (en) * | 2017-09-29 | 2020-04-16 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CA3091857A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| AU2019359475A1 (en) | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| WO2021009694A1 (en) * | 2019-07-17 | 2021-01-21 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN111690068B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| JP7814759B2 (ja) * | 2020-09-17 | 2026-02-17 | 上海霖羲致企業管理有限公司 | 二重特異性組換えタンパク質及びその使用 |
| EP4232069A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN117186227A (zh) * | 2020-12-23 | 2023-12-08 | 瑞泽恩制药公司 | 编码锚修饰的抗体的核酸以及其用途 |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| WO2023280287A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Interleukin-15 variants and uses thereof |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN113956346B (zh) * | 2021-10-26 | 2024-03-01 | 西安龙腾景云生物科技有限公司 | 一种重组白介素-15变体 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| EP4606384A1 (en) * | 2022-10-19 | 2025-08-27 | Astellas Pharma, Inc. | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment |
| WO2024170555A1 (en) * | 2023-02-14 | 2024-08-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Il-15 fusion proteins with improved properties |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2025147512A1 (en) * | 2024-01-02 | 2025-07-10 | Eli Lilly And Company | Immunogenicity assessment platform for biotherapeutic proteins |
| WO2025222129A2 (en) * | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP1718670B1 (en) * | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| MX2007006832A (es) * | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| US8313924B2 (en) | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| JP2013506404A (ja) | 2009-10-02 | 2013-02-28 | ロシュ グリクアート アーゲー | 抗体における非フコシル化の検出法 |
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| LT2794658T (lt) | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| WO2014207173A1 (en) | 2013-06-27 | 2014-12-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
-
2015
- 2015-03-06 EP EP15157911.7A patent/EP3064507A1/en not_active Withdrawn
-
2016
- 2016-03-07 HR HRP20192190TT patent/HRP20192190T1/hr unknown
- 2016-03-07 BR BR112017018975-5A patent/BR112017018975A2/pt not_active Application Discontinuation
- 2016-03-07 RS RS20191593A patent/RS59658B1/sr unknown
- 2016-03-07 ES ES16708154T patent/ES2763598T3/es active Active
- 2016-03-07 CN CN201680025275.8A patent/CN107636015A/zh active Pending
- 2016-03-07 US US15/556,282 patent/US10906952B2/en not_active Expired - Fee Related
- 2016-03-07 JP JP2017564951A patent/JP6757338B2/ja not_active Expired - Fee Related
- 2016-03-07 PT PT167081546T patent/PT3265478T/pt unknown
- 2016-03-07 HU HUE16708154A patent/HUE047818T2/hu unknown
- 2016-03-07 CA CA2978808A patent/CA2978808A1/en active Pending
- 2016-03-07 SI SI201630550T patent/SI3265478T1/sl unknown
- 2016-03-07 PL PL16708154T patent/PL3265478T3/pl unknown
- 2016-03-07 DK DK16708154.6T patent/DK3265478T3/da active
- 2016-03-07 EP EP16708154.6A patent/EP3265478B1/en not_active Revoked
- 2016-03-07 WO PCT/EP2016/054729 patent/WO2016142314A1/en not_active Ceased
-
2019
- 2019-12-11 CY CY20191101303T patent/CY1122494T1/el unknown
-
2020
- 2020-12-22 US US17/130,975 patent/US20210163564A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/565,942 patent/US20220324931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512168A5 (https=) | ||
| HRP20192190T1 (hr) | Fuzijski proteini koji sadrže vežući protein i polipeptid interleukin-15 sa smanjenim afinitetom za il15ra i njihova upotreba u terapiji | |
| JP2015502373A5 (https=) | ||
| JP2014088414A5 (https=) | ||
| JP2019531093A5 (https=) | ||
| PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| JP2021054859A5 (https=) | ||
| AR120585A1 (es) | Proteínas de unión a antígenos que se unen específicamente a mage-a | |
| JP2017504577A5 (https=) | ||
| JP2018523485A5 (https=) | ||
| HRP20170658T1 (hr) | Molekula bispecifičnog protutijela | |
| JP2014518615A5 (https=) | ||
| JP2018526970A5 (https=) | ||
| JP2014505463A5 (https=) | ||
| JP2019519227A5 (https=) | ||
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| PH12018502158A1 (en) | T cell receptors | |
| HRP20211788T1 (hr) | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| JP2012526530A5 (https=) | ||
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| JP2010006705A5 (https=) | ||
| MX2022004906A (es) | Moleculas de union especifica. |